Clinical Trials Logo

Clinical Trial Summary

The purpose of this trial is to determine whether delamanid is effective in the treatment of multidrug-resistant tuberculosis (MDR TB) in combination with other MDR TB medications during 6 months of treatment.


Clinical Trial Description

The primary objective of this trial is to evaluate the efficacy of delamanid administered orally as 100 milligrams (mg) twice daily (BID) for 2 months followed by 200 mg once daily (QD) for 4 months in combination with an optimized background treatment regimen (OBR) versus placebo with OBR during the 6-month Intensive Period of MDR TB treatment. Following the 6-month Intensive Period, OBR was administered alone during the Continuation Period for 12 to 18 months (from Month 7 up to Month 24). The trial also included a post-treatment follow-up period of 6 to 12 months (Month 19 to Month 24 to the end of Month 30). OBR given throughout the study was administered as per World Health Organization (WHO) guidelines and national treatment norms.

This trial is a multicenter, randomized, double-blind, stratified, placebo-controlled trial that was conducted globally in 2 parallel groups at 17 sites in 7 countries qualified to treat MDR TB. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01424670
Study type Interventional
Source Otsuka Pharmaceutical Development & Commercialization, Inc.
Contact
Status Completed
Phase Phase 3
Start date September 2, 2011
Completion date July 4, 2016

See also
  Status Clinical Trial Phase
Recruiting NCT02354014 - Pharmacokinetic Study to Evaluate Anti-mycobacterial Activity of TMC207 in Combination With Background Regimen (BR) of Multidrug Resistant Tuberculosis (MDR-TB) Medications for Treatment of Children/Adolescents Pulmonary MDR-TB Phase 2
Completed NCT02984579 - Line Probe Assay Evaluation Study N/A
Active, not recruiting NCT04260477 - Novel Triple-dose Tuberculosis Retreatment Regimen Phase 3
Completed NCT02727582 - Pharmacometric Optimization of Second Line Drugs for MDR Tuberculosis Treatment
Completed NCT01521364 - Drug Interaction Study Between Linezolid and Clarithromycin in Tuberculosis Patients Phase 4